Merck & Co., Inc. (MRK) has submitted an application to the FDA to expand the label of its RSV shot, Enflonsia.
The therapy is designed to protect infants from respiratory syncytial virus and was previously approved by the FDA.
The company's bid for a label expansion is currently under review, with a target action date set for March 22, 2027.
More on Stocks
Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.
Market sentiment intelligence for apps, funds & agents
Location
729 55 Ave SW
Calgary AB T2V 0G4
Canada
© 2026 Guavy Inc
